PD-1 Checkpoint Inhibitor Associated Autoimmune Encephalitis

Autor:	Stephanie Schneider, Silke Potthast, Paul Komminoth, Guido Schwegler, Steffen Böhm
Jazyk:	angličtina
Rok vydání:	2017
Předmět:	Autoimmune encephalitis PD-1 Checkpoint inhibitor Adverse event Non-small cell lung cancer Nivolumab Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	Case Reports in Oncology, Vol 10, Iss 2, Pp 473-478 (2017)
Druh dokumentu:	article
ISSN:	1662-6575 00047716
DOI:	10.1159/000477162
Popis:	Objective: To report first-hand narrative experience of autoimmune encephalitis and to briefly review currently available evidence of autoimmune encephalitis in cancer patients treated with immune checkpoint inhibitors. Setting: A case study is presented on the management of a patient who developed autoimmune encephalitis during nivolumab monotherapy occurring after 28 weeks on anti-PD-1 monotherapy (nivolumab 3 mg/kg every 2 weeks) for non-small cell lung cancer. Results: No substantial improvement was observed by antiepileptic treatment. After administration of 80 mg methylprednisolone, neurologic symptoms disappeared within 24 h and the patient fully recovered. Conclusions: Immune checkpoint inhibitor treatment can lead to autoimmune encephalitis. Clinical trial data indicate a frequency of autoimmune encephalitis of ≥0.1 to
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/832892bb0a11418683f261ed2aec187f Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.